Overcoming material constraints: aseptic filling solutions for rare or expensive APIs - Pharmaceutical Technology

Why does product loss occur in aseptic fill-finish, and how can a CDMO overcome material constraints to preserve as much drug product as possible? Why does product loss occur in aseptic fill-finish, and how can a CDMO overcome material constraints to preserve as much drug product as possible for clients with rare or expensive APIs? Sterile fill-finish is the critical final step of injectable drug production, ensuring patient safety by preventing microbial, bacterial, and particulate contamination in medications that enter the bloodstream directly. While fill-finish is a vital step in the production of these therapies, drug product loss is unfortunately…

Source: Pharmaceutical Technology